GENERAL OUTLOOK
RHU SPRINT – Synergy to accelerate therapeutic innovation in cutaneous T lymphoma
The SPRINT project aims to transform the care of patients with cutaneous T-cell lymphomas. These diseases affect 1 in 100,000 people every year, and their incidence has risen sharply in recent decades. This pathology severely impairs patients’ quality of life through skin damage, secondary skin infections, pain and fatigue, and survival is reduced in the advanced stages of the disease. Even today, only a minority of patients respond satisfactorily to existing treatments, and the disease is generally considered incurable.
Project leader: Professor Adèle de Masson, PU-PH – Université Paris Cité / AP-HP
> RHU SPRINT coordinating supervisor: Université Paris Cité
> Partners: AP-HP Hospitals, Domain Therapeutics, CHU Bordeaux (University Hospital of Bordeaux), ELLyE Leukemia Lymphoma patient association, European Reference Network for Rare Hematological Diseases, the GFELC Study Group of Cutaneous Lymphomas, HCL Civil Hospitals of Lyon, Inserm, TheraPanacea.
This project has benefited from State aid managed by the Agence Nationale de la Recherche under the France 2030 programme, reference: ANR-23-RHUS-0009.
